(382) Development of EGFR-Targeted Dual-Loaded Polymeric Nanoparticles for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that accounts for 15-20 % of all breast cancer cases [1]. TNBC is extremely challenging to treat using conventional treatment modalities like chemotherapy, radiotherapy, and surgery [2]. Our study aimed to solve the problems of TNBC treatment, such as low efficacy, toxicity, and poor site-specific drug delivery using dual-loaded antibody-targeted nanotherapeutics.